Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia (Q35607285)
Jump to navigation
Jump to search
scientific article published on 2 April 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia |
scientific article published on 2 April 2015 |
Statements
1 reference
Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia (English)
1 reference
John C Byrd
1 reference
Zachary A Hing
1 reference
Rose Mantel
1 reference
Kyle A Beckwith
1 reference
Daphne Guinn
1 reference
Erich Williams
1 reference
Lisa L Smith
1 reference
Katie Williams
1 reference
Amy J Johnson
1 reference
Amy M Lehman
1 reference
Jennifer A Woyach
1 reference
Rosa Lapalombella
1 reference
2 April 2015
1 reference
1 reference
125
1 reference
20
1 reference
3128-3132
1 reference
Identifiers
1 reference
1 reference
1 reference